Cox proportional HR for the risk of hospitalised HF in TNF antagonist users compared with nbDMARDs
| Analysis | HF HR (95% CI) (as treated) | HF HR (95% CI) (first exposure carried forward) |
|---|---|---|
| Any HF, total population | 0.84 (0.62 to 1.12) | 0.89 (0.69 to 1.15) |
| Known HF* | 0.95 (0.58 to 1.57) | 0.94 (0.62 to 1.43) |
| No known HF | 0.86 (0.58 to 1.27) | 0.94 (0.70 to 1.33) |
*Known HF was defined as persons with an acute care hospitalisation for HF during the 365 day baseline period prior to the start of follow-up. All models used the propensity score trimmed cohorts and included the 180-day prior cumulative oral glucocorticoid dosage, the number of HF hospitalisations and the use of loop diuretics.
nbDMARD, non-biological disease modifying antirheumatic drug; HF, heart failure